Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lirum Therapeutics
New York, NY, United Stateslirumtx.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
LX-101 has been evaluated in Phase 1a trials in patients with advanced, pretreated cancer where it was found to be well-tolerated and demonstrated single agent activity. Recent data shows LX-101's ability to inhibit TED-derived orbital fibroblasts, decrease inflammatory cytokines, reduce pro-fibrotic components, and modulate TED-derived T-cells.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Targeted therapyPrecision-engineered targeted therapyPayload-bearing targeted therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Lirum Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lirum Therapeutics.